Antiviral and immunoregulatory effects of curcumin on coxsackievirus B3-infected hepatitis.

Coxsackievirus B Curcumin Cytokine Heme oxygenase-1 Hepatitis

Journal

Virus research
ISSN: 1872-7492
Titre abrégé: Virus Res
Pays: Netherlands
ID NLM: 8410979

Informations de publication

Date de publication:
15 Oct 2023
Historique:
received: 19 05 2023
revised: 16 08 2023
accepted: 16 08 2023
pubmed: 26 8 2023
medline: 26 8 2023
entrez: 25 8 2023
Statut: ppublish

Résumé

Fulminant hepatitis is a life-threatening complication of coxsackievirus B (CVB) 3 infections. The condition may deteriorate to disseminated intravascular coagulopathy with markedly increased liver enzymes, inflammatory cytokines, and chemokines, which significantly induce local and systemic inflammation. Curcumin exhibits anti-inflammatory and antiviral characteristics in inflammatory and infectious diseases. Here we determined effects of curcumin on viral replications, cytokine and chemokine expressions, and liver damage in CVB3-infected Huh-7 cells. The mouse-adapted CVB3 strain was used to investigate the antiviral and anti-inflammatory effects of curcumin on CVB3-induced hepatitis in a mouse model. In vitro studies showed that curcumin reduced viral protein and titer levels and increased cell viability. Curcumin enhanced the heme oxygenase-1 (HO-1) protein level and decreased the levels of cleaved caspase-3 protein and mRNA of gene encoding C-X-C motif chemokine 10 in infected cells. In vivo studies showed that curcumin improved the survival rate and clinical scores in mice and reduced the viral titer in the liver during CVB3 infection. Moreover, the HO-1 levels were increased, and the cleaved caspase-3 levels were diminished in the CVB3-infected liver. Curcumin reduced the levels of interferon (IFN)-γ and monokine induced by IFN-γ in liver and levels of interleukin (IL)-8 in serum, but increased levels of regulated activation, normal T cell expression in liver and levels of IL-10 in serum of CVB3-infected mice. In summary, curcumin presents antiviral and anti-inflammation efficacies in CVB3 infection in vitro and in vivo; these results provide potential evidence on the feasibility of curcumin for clinical treatment.

Identifiants

pubmed: 37625648
pii: S0168-1702(23)00165-X
doi: 10.1016/j.virusres.2023.199203
pmc: PMC10485155
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

199203

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Yu-Jheng Lin (YJ)

Department of Microbiology & Immunology, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan.

Li-Chiu Wang (LC)

School of Medicine, I-Shou University, Kaohsiung 82445, Taiwan.

Huey-Pin Tsai (HP)

Department of Pathology,College of Medicine, National Cheng Kung University Hospital, National Cheng Kung University, Tainan 70401, Taiwan; Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan 70401, Taiwan.

Chia-Yu Chi (CY)

Department of Microbiology & Immunology, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan; National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Miaoli County 35053, Taiwan.

Chih-Peng Chang (CP)

Department of Microbiology & Immunology, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan; Center of Infectious Disease and Signaling Research, National Cheng Kung University, Tainan 70401, Taiwan; Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan 70401, Taiwan.

Shun-Hua Chen (SH)

Department of Microbiology & Immunology, College of Medicine, National Cheng Kung University, Tainan 70101, Taiwan; Center of Infectious Disease and Signaling Research, National Cheng Kung University, Tainan 70401, Taiwan; Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan 70401, Taiwan. Electronic address: shunhua@ncku.edu.tw.

Shih-Min Wang (SM)

Center of Infectious Disease and Signaling Research, National Cheng Kung University, Tainan 70401, Taiwan; Center for Infection Control, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 70401, Taiwan. Electronic address: pedwang@mail.ncku.edu.tw.

Classifications MeSH